Association between Ivermectin treatment and mortality in Covid-19: A hospital-based case-control study

Abstract

Introduction

: This study was designed to test the hypothesis that exposure to ivermectin in early disease prevents mortality due to COVID-19. A secondary objective was to see if the drug has any impact on the length of hospital stay among the survivors.

Methods

It was a hospital-based retrospective case control Study conducted at a tertiary teaching hospital in India. All patients with a diagnosis of COVID-19 who were admitted between 1st April and 15th May 2021 and received inpatient care were included. Important variables like demographic details, dates of admission and discharge or death, symptoms at the time of admission, comorbidities, severity of illness at the time of admission, whether ivermectin was administered or not during the course of the illness and other treatments received as part of the standard of care were retrieved from the medical records.

Results

Of the 965 patients who received inpatient care, 307 died during their hospital stay while 658 were successfully discharged. The proportion of cases treated with ivermectin was 17.26% among the non-survivors (53/307) and 17.93% among the survivors (118/658). The effect was statistically insignificant (crude OR = 0.954 ;95% CI: 0.668–1.364, p = 0.80). Among the survivors, the median length of stay was 11 days for patients who received ivermectin (IQR: 7–15) as well as for those who did not (IQR 7–16).

Conclusion

This study did not show any effect of ivermectin on in-patient mortality in patients with COVID-19 and there was no effect of the drug on the length of hospital stay among the survivors.

Introduction:

There has been a growing interest in the potential role of the anti-parasitic drug, ivermectin in the management of COVID-19 ever since it was reported to have an in-vitro activity against SARS-CoV-2. Some observational studies^,, a non-randomized interventional study and some RCTs^,, have reported quicker viral clearance with the use of ivermectin. However, other studies have not found any significant benefit.^,,, Clinical recovery and mortality benefit are clinically more relevant outcomes compared to viral clearance. An RCT of 400 patients with mild COVID-19 did not find any improvement in the time to resolution of symptoms with a five day course of Ivermectin (300 µg/kg) compared to placebo.

Some observational studies^3,, as well as some RCTs^{6, 11,,} have reported improved survival with ivermectin. However, another RCT reported no survival benefit. A few meta analyses of the available evidence have also noted possible reduction in mortality with this drug.^,, However, a recent review concluded that there was no survival benefit after excluding studies that were thought to have a high risk of bias. The WHO has advised against the use of this drug for COVID-19 outside clinical trials.

As the pandemic continues to spread and take lives worldwide and considering that ivermectin is a relatively safe and cheap drug, it is important to further investigate any possible mortality benefit of the drug in COVID-19. Given the low case fatality rate in mild disease very large RCTs are needed to detect with certainty any reduction in mortality. Hence a case control study is a pragmatic alternative. It provides a statistically efficient and logistically and economically feasible alternative for evaluating any survival benefit with the drug. This case control study was designed to assess the impact of ivermectin treatment on mortality when given early in the course of COVID-19 illness.

Methods And Materials

The primary objective of this study was to estimate the association of ivermectin treatment with mortality in patients admitted with COVID-19. A secondary objective was estimation of the extent of reduction, if any, in duration of hospital stay in survivors who received ivermectin.

It was a hospital-based retrospective case control Study conducted at a tertiary teaching hospital in eastern India. Ethical clearance was obtained from the Institutional Ethics Committee, All India Institute of Medical Sciences (AIIMS), Patna. All patients with a diagnosis of COVID-19 who were admitted to the hospital between 1st April and 15th May 2021 and received inpatient care were included in the study. Patients who were admitted nominally but allowed to go on home isolation were excluded. Those patients who died during their hospital stay were selected as cases while those who were discharged alive were selected as controls. Ivermectin, taken by any patients, case or control, was the exposure of interest.

A semi-structured proforma was used to collect data of all the patients included in the study. Important variables such as demographic data, dates of admission and discharge or death, clinical signs and symptoms at the time of admission, history of comorbidities like hypertension, diabetes mellitus, cardio-vascular disease, respiratory illness, chronic or acute liver or kidney dysfunction etc., severity of illness at the time of admission (mild, moderate or severe) as defined in the guidelines issued by the Ministry of Health and Family Welfare, Government of India, whether ivermectin was administered or not during the course of the illness (either before or after the admission) and other treatments received as part of the standard of care were retrieved from the case notes obtained from the medical records department of the institute.

All data were entered into MS Excel using proper code for each variable. Statistical analysis was performed using Stata, version10 (Stata Corp, Texas, USA). Continuous variables were tested for normality using Shapiro-Wilks test and expressed as mean with 95% confidence interval in the case of normal data and as median with Inter-quartile range in the case of non-normal data. Categorical variables were expressed as percentages. T-test for difference of mean for two groups was applied after checking the equality of variance using F-test for normally distributed continuous variables. Mann-Whitney Wilcoxon U-test was applied for testing the significance of distribution of variables in the two groups. Chi-square test was applied for testing the association between two categorical variables. Further, age, which was entered as a continuous variable, was categorized into three dummy variables, viz. < 25 years, 25–44 years and > 45. Similarly, disease severity was categorized into three dummy variables, viz. mild, moderate and severe. Crude odds ratio with 95% confidence interval was estimated for ivermectin usage in relation to the survival and non-survival groups.

Results

Altogether, 1175 patients with COVID-19 were admitted between 1st April and 15th May 2021. However, 210 of these patients were excluded from the study as they were allowed to go on home leave and hence did not have adequate inpatient documentation. Of the remaining 965 patients, 307 died during their hospital stay while 658 were successfully discharged (Figure 1). Table-1 presents the comparison of demographic and clinical factors such as signs and symptoms at the time of admission, the presence of comorbidities like hypertension, diabetes, cardio-vascular diseases, asthma, chronic kidney disease etc. and disease severity on admission between those who received ivermectin and those who did not. Except cough and weakness, all factors were similarly distributed between the two groups (Chi-square test p-value > 0.05). 

Table-1: Comparison of demographic and clinical factors between patients receiving and not receiving ivermectin  

Table-2 presents the comparison of various drugs administered between patients who were treated  with ivermectin and those who were not. Altogether 171 (17.7%) received ivermectin in addition to other medicines such as antibiotics (168), steroids (161), remdesvir (83), toclizumab (4) and itolizumab (1). The remaining 794 who did not receive ivermectin were also treated with the above medicines as per the institutional protocol and the clinical judgement of the treating team. Usage of all drugs between the two groups was comparable (Chi-square test p-value>0.05). 

Table-2: Comparison of usage of various drugs between patients receiving and not receiving ivermectin   

Table-3 presents the effect of ivermectin on survival. The proportion of cases treated with ivermectin was 17.26% among the non-survivors and 17.93% among the survivors. The effect was statistically insignificant (crude OR = 0.954 ;95% CI: 0.668 – 1.364, p=0.80). 

A logistic regression analysis was performed with bootstrapping after 50 replications of the random data set to estimate the effect of ivermectin on the outcome i.e. survival status after controlling for each of the confounders. Even after adjusting for the confounders, the effect was statistically not significant (adjusted OR = 0.96; 95% CI: 0.66 – 1.39, p= 0.819). The logistic regression model was found to fit well (Wald chi-square with 5  d.f. = 41.52, P =0.00001). The AIC was 1155.44 and BIC was -29.33.

Table-3: Association of ivermectin with survival 

*-Crude OR; **-Adjusted OR

Effect of ivermectin on duration of hospital stay among the survivors 

Table-4 presents the duration of hospital stay in days. It was tested for normality using Shapiro-Wilk W test. It was found to be non-normally distributed (z-statistic = 10.261, p-value=0.0001). Hence Mann-Whitney Wilcoxon U-test was applied to compare the distribution of hospital stay between the survivors who received ivermectin and those who did not. There was no significant difference between the two group (p=0.8759). 

Table-4: Comparison of duration of hospital stay (in days) among survived Covid-19 patients

Discussion

The study did not find any association between ivermectin use and survival in patients with COVID-19. This is in agreement with the existing WHO guidelines that do not advocate the use of this drug outside of clinical trials.²²

An RCT of 400 patients with mild COVID-19 did not find any improvement in the time to resolution of symptoms with a five-day course of Ivermectin (300 µg/kg).¹² More recently, an RCT of 490 patients with mild to moderate COVID-19 with comorbidities did not find any reduction in progression to severe disease with a five-day course of ivermectin 0.4 mg/Kg body weight. RCTs evaluating the effect of ivermectin on mortality have given conflicting results. Some of the earlier meta-analyses had concluded a survival benefit with the drug.^{18, 19, 20} However, a recent review that excluded trials thought to have a high risk of bias found no survival benefit.²² It could be argued that with the very low case fatality rates reported with mild and moderate COVID-19 the RCTs were insufficiently powered to detect any potential survival benefit with the drug. Therefore, a case control study is a pragmatic design to study any possible association between survival and the usage of ivermectin in early COVID-19. The authors feel that the findings of this study will be a useful contribution to the current body of evidence on the effect of ivermectin on mortality in COVID-19. A secondary objective of this study was to see if there was any reduction in the length of hospital stay among the survivors who had received ivermectin. No difference was observed in the duration of hospital stay between patients who received ivermectin and those who did not. Thus no recommendation can be made on the basis of this study for the use of ivermectin in COVID-19.

Despite the demonstration of in vitro anti-viral activity of ivermectin against SARS-COV-II, a compelling evidence of its clinical utility in COVID-19 remains elusive. This is probably because the concentration of the drug at which its in vitro antiviral activity was noted¹ is difficult to achieve with pharmacological doses. Doses as high as 90 to 120 mg per dose have been demonstrated to be safe in human beings and remain potential subjects of future research for their role in the treatment of COVID-19.

The study has some obvious limitations. As it was a case-control study, its results cannot substitute the findings of high quality RCTs but only complement them. As it was based on retrospective case note analysis, the accuracy of the data was dependent upon the documentations done by the treating teams. As many of the patients had already received the drug prior to their admission, the possibility of a recall bias cannot be ruled out. Moreover, the regime used by the patients was not standardized. While 12 mg tablets given once daily were being used in most adults the duration of treatment was not always the same.

Conclusion

This study did not show any effect of ivermectin on in-patient mortality in patients with COVID-19. Similarly, there was no effect of the drug on the length of hospital stay among the survivors.

Declarations

Authorship Statement: All authors meet the ICMJE authorship criteria. 

Conflicts of interest: None

Funding: None

References

1. Caly L, Druce JD et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research, June 2020; 178: 1-4.   DOI: https://doi.org/10.1016/j.antiviral.2020.104787
2. Alam MT, Murshed R et al. A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline. J Bangladesh Coll Phys Surg 2020; 38: 10-15. DOI: https://doi.org/10.3329/jbcps.v38i0.47512  
3.  Khan MSI, Khan MSI et al. Ivermectin treatment may improve the prognosis of patients with COVID-19. Archivos de Bronconeumologia 2020. 56(12): 828-30
4.  Espitia-Hernandez G, Munguia L et al. Effects of Ivermectin-azithromycin-cholecalciferol combined therapy on COVID-19 infected patients: A proof of concept study. Biomedical Research 2020; 31 (5): 129-133
5.  Ahmed S, Karim MM et al. A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. International Journal of Infectious Diseases (Available online since 02/12/2020).                                             DOI: https://doi.org/10.1016/j.ijid.2020.11.191
6.  Mahmud R, Rahman MM et al. Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial. J Int Med Res. 2021 May;49(5):3000605211013550. DOI: 10.1177/03000605211013550.
7.  Babalola OE, Bode CO, Ajayi AA et al. Ivermectin shows clinical benefits in mild to moderate COVID19: a randomised controlled double-blind, dose-response study in Lagos. QJM-Int J Med. 2021.114(11):80-88 DOI:10.1093/qjmed/hcab035
8.  Camprubi D, Almuedo-Riera A et al. Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients. PLoS ONE 15(11): e0242184. DOI: https://doi.org/10.1371/journal. pone.0242184
9.  Chowdhury A, Shahbaz M, Karim M et al. A Comparative Study on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin Therapy on COVID-19 Patients. EJMO. 2021; 5(1): 63-70
10.  Mohan A, Tiwari P, Suri TM et al. Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial. J Infect Chemother. 2021 Dec;27(12):1743-1749. DOI: 10.1016/j.jiac.2021.08.021.
11.  Ravikirti, Roy R et al. Evaluation of Ivermectin as a Potential Treatment for Mild to Moderate COVID-19: A Double-Blind Randomized Placebo Controlled Trial in Eastern India. J Pharm Pharm Sci. 2021; 24:343-350. DOI: 10.18433/jpps32105.
12.  López-Medina E, López P, Hurtado IC et al. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial. JAMA. 2021 Apr 13;325(14):1426-1435. DOI: 10.1001/jama.2021.3071.
13. Hector C, Roberto H. Safety and Efficacy of the combined use of ivermectin, dexamethasone, enoxaparin and aspirin against COVID-19 – The I.D.E.A. Protocol. Journal of Clinical Trials. 2021;11(3):1-6
14. Rajter JC, Sherman MS et al. Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019 - The ICON Study. CHEST 2020.  Available at: https://journal.chestnet.org/action/showPdf?pii=S0012-3692%2820%2934898-4 (Accessed: 17/12/2020)
15.  Hashim HA, Maulood MF et al. Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq. medRxiv 2020.10.14. DOI:   https://doi.org/10.1101/2020.10.26.20219345
16.  Niaee MS, Namdar P, et al. Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial. Asian Pac J Trop Med 2021; 14:266-73
17. Gonzalez JLB, González Gámez M, Enciso EAM, et al. Efficacy and safety of Ivermectin and Hydroxychloroquine in patients with severe COVID-19. A randomized controlled trial. medRxiv 2021
18.  Abdulamir AS, Ahmed S, Asghar A, Hill A et al. Preliminary meta-analysis of randomized trials of ivermectin to treat SARS- CoV-2 infection. Research Square 2021
19.  Bryant A, Lawrie TA et al. Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. Am J Ther. 2021 Jun 21;28(4):e434-e460. DOI: 10.1097/MJT.0000000000001402.
20. Karale S, Bansal V, Makadia J et al. A Meta-analysis of Mortality, Need for ICU admission, Use of Mechanical Ventilation and Adverse Effects with Ivermectin Use in COVID-19 Patients. medRxiv 2021.05.04 DOI: https://doi.org/10.1101/2021.04.30.21256415
21.  Hill A, Mirchandani M, Pilkington V. Ivermectin for COVID-19: Addressing potential bias and medical fraud. Open Forum Infectious Diseases, February 2022; 9(2):1-3
22. Lamontagne F, Agoritsas T, Macdonald H et al. A living WHO guideline on drugs for covid-19. BMJ2020;370:m3379 | DOI: 10.1136/bmj.m3379
23. Lim SCL, Hor CP, Tay KH. Effect of Ivermectin on Disease Progression among Adults with Mild to Moderate COVID-19 and Comorbidities. JAMA Intern Med. Published online February 18, 2022. DOI: 10.1001/jamainternmed.2022.0189
24.  Peña‐Silva R., Duffull S.B., Steer A.C., Jaramillo‐Rincon S.X., Gwee A., Zhu X. Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID‐19. Br J Clin Pharmacol. 2020 Jul 17:14476. bcp.
25.  Guzzo CA, Furtek CI, Porras AG, Chen C, Tipping R, Clineschmidt CM, Sciberras DG, Hsieh JY, Lasseter KC. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol. 2002 Oct;42(10):1122-33. DOI: 10.1177/009127002401382731.